FDA concedes Glooko’s Mobile Insulin Dosing System
Glooko’s Mobile Insulin Dosing System aims to make it easier and more effective for physicians and patients to titrate long-acting insulin between visits
Glooko declared that the US FDA has conceded its Mobile Insulin Dosing System (MIDS) for the titration of long-acting insulin for people with type 2 diabetes.
The system includes access to a patient’s blood glucose (BG) data directly from their glucose meter so people with diabetes (PWDs) do not have to manually enter their fasting blood glucose, and healthcare providers (HCPs) access accurate diabetes data in the MIDS module. MIDS analyzes a patient’s fasting blood glucose levels and recommends insulin dose adjustments based on the HCP’s pre-configured treatment plan and/or published clinical guidelines so patients can quickly and easily get to their optimal insulin dose.
Dr. Michael Greenfield, Chief Medical Officer at Glooko said “Managing long-acting insulin can be a challenge for people with diabetes because it requires patients to regularly change their doses based on their own calculations using fasting glucose values. This can be daunting and unreliable.”
The presence of mobile technologies provides a way to support and educate patients on insulin in a continuous and contextual manner. With MIDS, Glooko has set out to ease and improve adherence to insulin therapy and drive overall better health outcomes among people with type 2 diabetes.